UFA
TEVA icon

US Financial Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

US Financial Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-164
Closed -$10K – 567
2015
Q1 		$10K Buy
+164
New +$9.54K 0.01% 265

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

US Financial Advisors's TEVA Position: Q2 2015 in Review

US Financial Advisors sold out of Teva Pharmaceuticals (TEVA) in Q2 2015, closing a stake of 164 shares — an estimated $10K sold.

US Financial Advisors first reported a position in TEVA in Q1 2015 and held it in 1 quarter. The position peaked at $10K in Q1 2015. 818 funds tracked by Wall St. Rank hold TEVA as of Q2 2015.

  • US Financial Advisors reported no remaining Teva Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • US Financial Advisors sold 164 Teva Pharmaceuticals shares in Q2 2015, an estimated $10K.
  • US Financial Advisors first reported a position in Teva Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • US Financial Advisors's Teva Pharmaceuticals position peaked at $10K in Q1 2015.
  • 818 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2015.

Based on US Financial Advisors's 13F filing for Q2 2015, filed 11 Aug 2015.